Skip to content
Bipartisan legislation reintroduced in the House on Feb. 21 would encourage the development of small-molecule drugs by eliminating the “pill penalty” in the Inflation […]
EPIC Act introduced to correct IRA’s ‘pill penalty’ Read More »
“Kidney disease is a major and growing public health concern,” LaVarne A. Burton, American Kidney Fund President and CEO, said in an interview with
Kidney Action Week: 4 things you need to know about kidney disease Read More »
The Centers for Medicare & Medicaid Services (CMS) recently announced the 2025 selection of 15 drugs covered under Medicare Part D for price “negotiations”
The role of the patient voice in CMS drug price ‘negotiation’ Read More »
February 28 is Rare Disease Day, and in observance, the Biotechnology Innovation Organization (BIO) is highlighting how it is working with member companies to
BIO celebrates release of FDA Rare Disease Innovation Hub 2025 strategic plan Read More »
Drug development in the rare disease space has seen a vast amount of innovation in recent years, with a number of groundbreaking therapies coming
Goodwin Rare Disease Symposium: ‘So much opportunity, so much unmet need’ Read More »
When it comes to biotech M&A, 2024 wasn’t a great year, but it wasn’t “horrible,” according to analysts at the BIO CEO & Investor
M&A comeback may face political headwinds, say BIO CEO panelists Read More »
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs Read More »
Seeking biotech-friendly policy from the new administration and Congress will be daunting and perhaps confusing, but there are still a lot of potential wins
BIO CEO 2025: Challenges and opportunities in the new administration Read More »
Despite a pressing demand, schizophrenia has had limited treatment. “Roughly 1% of the entire world population has schizophrenia,” said Boobalan Pachaiyappan, Managing Director and
BIO CEO 2025: New solution for the challenge of schizophrenia Read More »
The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do
BIO CEO 2025: AI is a tool – not magic Read More »
